BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//European Brain Council (EBC) - ECPv6.15.19//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:European Brain Council (EBC)
X-ORIGINAL-URL:https://www.braincouncil.eu
X-WR-CALDESC:Events for European Brain Council (EBC)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221007
DTEND;VALUE=DATE:20221010
DTSTAMP:20260414T221806
CREATED:20220927T134839Z
LAST-MODIFIED:20220927T134839Z
UID:40974-1665100800-1665359999@www.braincouncil.eu
SUMMARY:13th International Autism-Europe Congress
DESCRIPTION:The 13th International Autism-Europe Congress is the first full online Congress with high quality access to its sessions\, presentations\, workshops\, discussion panels and more. You can join in person as well\, in the historical city of Cracow. The Congress brings expertise from around the world to promote a positive vision for autistic people and their families. \n“Happy Journey through Life” is the theme of the Congress – to highlight the importance of taking a lifespan perspective on autism research and practice\, with the promotion of wellbeing for all being the focal point. \nEBC looks forward to presenting the following sessions: \n\nThe value of treatment study: Autism care pathway in Europe (7 October\, 17:00-18:00; Oral Session)\n\nAutism is a lifelong complex neurodevelopmental condition of early onset that affects brain development and behaviour\, characterised by difficulties in social communication\, restricted and repetitive patterns of behaviour\, interests or activities\, and sensory issues which have significant consequences in daily life.  \nThe Value of Treatment (VOT) study results on autism care pathway in Europe will be presented. Early intervention can play a crucial role in the earlier social-communicative and emotional development which will act as a bridge for other more complex abilities. The primary goal of early intervention is to maximize functional independence and quality of life. Despite its great societal and personal impact\, Europe-wide consensus and support for early detection\, diagnosis\, and intervention of autism are lacking.   \n\nAutism with associated epilepsy care pathway in Europe (8 October\, 9:00-13:00; Poster Presentation)\n\nAutism and epilepsy are frequently associated. The prevalence of epilepsy in autism is greater than in the general population. Electroencephalography (EEG) has been used to investigate epilepsy in autism. EEGs are recommended if there is clinical suspicion of epilepsy. However\, the clinical identification of seizures in autism can be challenging because some of the features of seizures such as staring spells\, non-responsiveness and repetitive motor behaviours are also manifestations of autism.  \nAssociated conditions in autism such as epilepsy have a substantial impact on the well being of autistic people and their families\, contribute to reduced quality of life and may increase premature mortality. Despite this\, there is a current lack of studies assessing the journey experienced by autistic children with co-occurring epilepsy and their families in Europe. The VOT study on Autism with associated epilepsy care pathway in Europe will be presented. 
URL:https://www.braincouncil.eu/event/13th-international-autism-europe-congress/
LOCATION:Krakow\, Poland
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221013
DTSTAMP:20260414T221806
CREATED:20220325T132157Z
LAST-MODIFIED:20220804T122043Z
UID:35134-1665446400-1665619199@www.braincouncil.eu
SUMMARY:Brain Innovation Days: Connecting Brains
DESCRIPTION:  \nThis year’s Brain Innovation Days event will centre around Connecting Brains; bringing together the current and future generations of brain research and innovation.  \n\n\n\nThe focus of the 2022 event will be to enable space and opportunity for open discussion and showcasing\, prioritising matchmaking and networking within the community\, particularly of stakeholders who may not have the opportunity to connect in their day-to-day. \n\n\n\n\n\n\nPre-event matchmaking would be encouraged through a dedicated platform in order to facilitate interaction on the day and programme details will be shared between March and May 2022 in order to attract a wider audience and kickstart networking opportunities.  \n\n\n\n\n\n\nThe 2nd Brain Innovation Days Pitch Competition will take place on the day\, with five pre-selected finalists battling live for the jury and public prizes for Best Pitch \n\n\n\n\n\n\nAn Innovation Corner will be set up for companies to showcase their tangible tools and devices and for researchers to present posters\, an area that will be open on the 11th in the afternoon during the EBRA Final Conference and throughout the day on the 12th and host a guided tour during the Networking Reception on 12 October.  \n\n\n\n\n\n\nThe day will host a series of How-To sessions focused on business and networking skills\, a high-level investor panel\, a policy-focused roundtable discussion on research funding\, countless networking opportunities (both in groups and one-on-one) and exciting Brain Talks. \nA pre-event\, 12-episode season 2 of the Brain Talks podcast series will follow the chosen theme of the 2022 BIDs\, also involving members of EBC\, pulling in the perspective of scientists\, clinicians\, patients and more.  \nDiscover the programme and register here!
URL:https://www.braincouncil.eu/event/brain-innovation-days-connecting-brains/
LOCATION:Brussels\, Belgium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221011T080000
DTEND;TZID=UTC:20221011T140000
DTSTAMP:20260414T221806
CREATED:20220328T093117Z
LAST-MODIFIED:20220804T122055Z
UID:35183-1665475200-1665496800@www.braincouncil.eu
SUMMARY:European Brain Research Area Final Conference
DESCRIPTION:  \nThe European Brain Research Area (EBRA) project partners are delighted to invite you to the upcoming Final Conference\, which will take place on 11 October 2022 in Brussels\, Belgium. \n\n\n\nFour years have already passed and plenty of work is to be presented this coming October\, including the EBRA Landscape Analysis\, the Shared European Brain Research Agenda (SEBRA) as well as the work undertaken by the six EBRA Clusters. The event will be an occasion to bring the wider brain research community and key players together\, to discuss key aims of the project: the current state of brain research in Europe\, increased patient engagement and public awareness\, research infrastructures and data sharing and the future potentials and need for a brain health partnership going forward. \nCollaboration and cooperation in the brain research area remain more important than ever and the EBRA Final Conference will be a major milestone to ensure unification and commitment to the future of brain research in Europe. \nThe EBRA Final Conference will be held in conjunction with the Brain Innovation Days\, taking place on 11-12 October 2022 in Brussels. \nDiscover the programme and register here.
URL:https://www.braincouncil.eu/event/european-brain-research-area-final-conference/
LOCATION:Brussels\, Belgium
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221015
DTEND;VALUE=DATE:20221019
DTSTAMP:20260414T221806
CREATED:20211116T141423Z
LAST-MODIFIED:20221026T122923Z
UID:32607-1665792000-1666137599@www.braincouncil.eu
SUMMARY:EBC at the 35th European College of Neuropsychopharmacology (ECNP) Congress
DESCRIPTION:The annual European College of Neuropsychopharmacology (ECNP) Congress is Europe’s premier scientific meeting for disease-oriented brain research\, annually attracting more than 5\,000 psychiatrists\, neuroscientists\, neurologists and psychologists from around the world. \nThe European College of Neuropsychopharmacology (ECNP) is an independent scientific association dedicated to the science and treatment of disorders of the brain. It is the largest non-institutional supporter of applied and translational neuroscience research and education in Europe. \nEBC was pleased to take part in the ECNP Congress which took place on 15-18 October 2022 in Vienna (Austria) and virtually. Alongside an Exhibition Stand in the exhibition area (booth 16)\, EBC had a campfire session The value of early intervention and continuity of care for mental disorders take place on 17 October at 11:15 – 12:00. The session\, moderated by Prof. Judit Simon\, featured the following presentations: \n\nThe value of early intervention for associated epilepsy in autism by Prof. Celso Arango\, Spain\nThe value of early intervention and continuity of care for mood disorders by Prof. Allan Young\, United Kingdom\n\nAdditionally\, the EBC project the European Brain Research Area (EBRA) was showcased at the congress through a poster. \nWe look forward to the next year’s congress which will take place from 7-10 October 2023 in Barcelona (Spain)!
URL:https://www.braincouncil.eu/event/35th-ecnp-congress/
LOCATION:Vienna\, Austria
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221016
DTEND;VALUE=DATE:20221021
DTSTAMP:20260414T221806
CREATED:20220427T135333Z
LAST-MODIFIED:20221103T084552Z
UID:36088-1665878400-1666310399@www.braincouncil.eu
SUMMARY:European Congress of Neurosurgery 2022
DESCRIPTION:The European Congress of Neurosurgery 2022 (EANS2022) took place on 16-20 October in Belgrade\, Serbia. The European Association of Neurosurgical Societies (EANS) is both an independent federation of European national neurosurgical societies and a fast-developing association of individual neurosurgeons from around the world. \nThe Congress theme – Trends\, Insights\, Innovations: Neurosurgery beyond Technology – addressed the complex relation between technological advances and human ingenuity in the field of neurosurgery. The age of rapid technological progress\, artificial intelligence\, machine learning and virtual reality in the 21st century has brought many benefits to neurosurgery\, but also many challenges. \nAfter two turbulent pandemic years\, the Congress in Belgrade represented the regathering of European and world experts in neurosurgery. It provided an excellent opportunity for sharing experiences and exchanging ideas through the top-level scientific program\, aimed at providing a comprehensive insight into these benefits and challenges and striking the right balance between technology and human (neurosurgeons’) touch. \nEBC President\, Prof. Wolfgang Oertel\, was pleased to take part in the congress and present “EBC and the Brain Policies in Europe” during a plenary “Brain & Spine\, The Official Journal of EANS & EUROSPINE” on 19 October 2022 at 13:50-14:30. \nFind more information on the congress here.
URL:https://www.braincouncil.eu/event/european-congress-of-neurosurgery-2022/
LOCATION:Belgrade\, Serbia
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221017T111500
DTEND;TZID=UTC:20221017T120000
DTSTAMP:20260414T221806
CREATED:20220506T115240Z
LAST-MODIFIED:20221017T074652Z
UID:36340-1666005300-1666008000@www.braincouncil.eu
SUMMARY:The value of early intervention and continuity of care for mental disorders | ECNP Congress
DESCRIPTION:Mood Disorders are a common\, chronic\, severe\, complex and costly group of predominantly recurrent psychiatric illness that can be devastating for the affected individual and their families and impose a high health care related burden. Major depressive disorder and bipolar disorder are the main diagnostic categories in mood disorders. There is a significant clinical need for more effective detection and better delivered treatments for these illnesses. Major depressive disorder accounts for the predominant burden associated with both unipolar and bipolar disorder. However\, both the identification and management of bipolar depression are more challenging\, since bipolar depression differs little symptomatically from unipolar depression and responds poorly to traditional antidepressants\, which may also induce a switch to mania and/or cause rapid cycling. The physical health of people with all mood disorders is compromised and their life expectancy markedly reduced. The aim of a care pathway is to enhance quality of care by improving patient outcomes\, promoting patient safety\, increasing patient satisfaction\, and optimizing the use of resources. \nWith this in mind\, the European Brain Council (EBC) initiated in 2019 a study called the Value of Treatment (VoT) to address diagnostic and treatment gaps for brain (including mental and neurological) disorders. The EBC deemed it necessary to add case studies on mental health conditions such as major depressive disorder and autism. Disease treatment pathways should run from detection in the community through primary and secondary care to specialist clinics. Early intervention and continuity of care are very necessary to effectively manage patients’ mood disorders and overall health.
URL:https://www.braincouncil.eu/event/the-value-of-early-intervention-and-continuity-of-care-for-mental-disorders-ecnp-congress/
LOCATION:Vienna\, Austria
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221018T173000
DTEND;TZID=UTC:20221018T183000
DTSTAMP:20260414T221806
CREATED:20220916T084617Z
LAST-MODIFIED:20230224T095704Z
UID:40694-1666114200-1666117800@www.braincouncil.eu
SUMMARY:Rethinking the early detection and diagnosis of Alzheimer’s disease | Alzheimer Europe Conference
DESCRIPTION:Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health and health systems‘ needs. AD represents between 60 and%70% of the dementia cases. It is still diagnosed too late\, when the symptoms become more evident as the disease progresses. \nAD is now portrayed as a continuum consisting of three stages: an asymptomatic preclinical phase\, a mild cognitive impairment (MCI) phase\, and dementia. To match this continuum\, current research efforts are now focussing on the earlier stages of the disease (MCI stage)\, when it is believed that a therapeutical intervention at that stage would slow or prevent disease progression. \nThe speakers of the evening symposium “Rethinking the early detection and diagnosis of Alzheimer’s disease”\, set to take place on 18 October 2022 from 17:30-18:30 (Bucharest time) at the Alzheimer Europe Conference\, will present a research-driven project RETHINKING Alzheimer’s disease. The project is led by the European Brain Council (EBC) in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA) with the aim to identify the roadblocks to early detection and diagnosis of AD and will propose new clinical pathways building bridges between all stakeholders to improve the current situation and prepare for the future. \nSpeakers’ biographiesKevin Quaid\, Vice-Chairperson\, European Working Group of People with Dementia  \nLimerick native Kevin Quaid was diagnosed with Lewy Body Dementia in 2017 aged 53\, after being diagnosed firstly with Parkinsons. He is a member of the Irish Dementia Working Group as well as vice chair of the European Working Group of People with dementia and co founder of Lewy body Ireland  \nKevin is an avid GAA fan and speaks about the fighting spirit of the Limerick hurling team in 2018 and the fact they never gave up. He brings that same spirit to his life with dementia.  \nKevin is married to Helena. He has three children\, three stepchildren and five grandchildren. This family man is an adventurer who spent time in Australia and loves to travel.  \nAfter his diagnosis Kevin realised there was a lack of information about his particular form of dementia and wrote a book called “Lewy Body Dementia\, Survival and Me”. He was one of the first patients in the world to write a book about Lewy Body Dementia from the patients point of view as well as his families point of view\, He has since written a second book called “I am KEVIN not Lewy” . He is now an active advocate and through his work with the Irish Dementia Working Group supported by The Alzheimer Society of Ireland raises awareness about the condition through speaking engagements and media appearances. \nWiesje van der Flier\, Scientific Director\, Alzheimer Center Amsterdam  \nWiesje van der Flier (1975) is full professor and scientific director of Alzheimer center Amsterdam at Amsterdam UMC\, the Netherlands\, where she works since 2004. She studied neuropsychology at the University of Utrecht. In addition\, she is clinical epidemiologist. She leads the Amsterdam Dementia Cohort\, an ongoing memory-clinic based cohort including over 6000 patients with deep phenotyping (MRI\, EEG\, CSF biomarkers\, and PET) and linked biobank (blood\, DNA\, CSF). The Amsterdam Dementia Cohort is at the basis of many of the studies performed at Alzheimer center Amsterdam. Van der Flier has been (co)promotor of >20 theses and is currently supervising ~10 PhD projects. Van der Fliers main research areas are looking for the origin of AD\, diagnosis&prognosis\, and intervention&prevention. Van der Flier leads ABOARD (A Personalized Medicine Approach for Alzheimer's Disease)\, a Dutch public-private partnership of than 30 partners. Together with colleague Philip Scheltens\, she has written a book\, het Alzheimermysterie\, which was published by the Arbeiderspers.  \nLenka Krajčovičová\, Assistant Professor\, Masaryk University  \nLenka Krajčovičová has a PhD in neurology at Masaryk University in Brno (Czech Republic). Her scientific topics include neurodegenerative disorders – Parkinson´s disease and Alzheimer´s disease in particular\, movement disorders\, cognitive disorders.  \nShe has been involved in numerous research projects such as Microbiome in neurodegenerative diseases with cognitive impairment (Czech national recovery program)\, Diagnostics of Lewy body diseases in the prodromal stage based on multimodal data analysis\, supported by Ministry of Health of the Czech Republic\, Modulation of cognition and brain connectivity by noninvasive brain stimulation in patients with mild cognitive impairment due to Alzheimer's disease\, supported by Ministry of Health of the Czech Republic\, Effect of intensive dance-exercise intervention on cognitive function and changes of brain plasticity in healthy seniors and patients with mild cognitive impairment in early stage of Alzheimer´s disease\, supported by Ministry of Health of the Czech Republic and Pre-clinical genotype-phenotype predictors of Alzheimer´s disease and other dementia (APGeM)\, supported by EU Joint Program – Neurodegenerative Disease Research.   \nLenka Krajčovičová is a member of the Czech medical society\, the Czech neurological society\, the Section of cognitive neurology\, the Section of extrapyramidal neurology and the Czech society for clinical neurophysiology.    \nLydia Lanman\, Senior Global Policy Leader\, Roche  \nLydia Lanman is a senior Global Policy Leader at Hoffmann-La Roche and is responsible for leading Roche efforts across a variety of global health policy areas. Her area of expertise is in brain health and Alzheimer's disease.  \nLydia joined the pharmaceutical industry in Canada in 2007\, where she has led a variety of national policy\, government relations and market access efforts at two pharmaceutical firms. Prior to joining pharma\, Lydia worked in various senior advisory roles in Canada\, providing strategic advice directly to Ministers and Deputy Ministers of Health\, both federally and provincially\, on the development of health care policy\, health system design and intergovernmental relations.  \nLydia holds a Bachelor of Arts in Political Science and a Master of Arts in Political Science and Public Health\, both from the University of Alberta. Her graduate work focused primarily on Canadian and international health care reforms. \nFor privacy reasons YouTube needs your permission to be loaded. For more details\, please see our Privacy Policy.I Accept
URL:https://www.braincouncil.eu/event/alzheimer-europe-conference-rethinking-the-early-detection-and-diagnosis-of-alzheimers-disease/
LOCATION:Bucharest\, Romania
END:VEVENT
END:VCALENDAR